MAP3K5 and cardiac hypertrophy: Direct binding of dual specificity phosphatase 9 (DUSP9) or N-acetylgalactosaminyltransferase 4 (GALNT4) to ASK1 also reduce its activation, which protects against pathologic cardiac hypertrophy in vitro and in vivo [101,102].